Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
about
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for interventionTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesTargeting the adaptive molecular landscape of castration-resistant prostate cancerMolecular Imaging of Prostate CancerAbiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityTargeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Molecular pathways and targets in prostate cancerBeyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Safety of antiandrogen therapy for treating prostate cancer.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.Androgen receptor: structure, role in prostate cancer and drug discovery.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsCurrent advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Molecular imaging of urogenital diseases.Update in systemic therapy of urologic malignancies.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsEvolution of androgen receptor targeted therapy for advanced prostate cancer.Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerAdvances in systemic therapies for metastatic castration-resistant prostate cancer.Nonmetastatic castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer: time for innovation.Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.Sequences and combinations of multifaceted therapy in advanced prostate cancer.Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
P2860
Q21129293-ABDBC21A-0E2A-46D1-B6AB-BAB3CED7A761Q26750620-958ADA92-6D7D-45E8-93B1-77C2E80F641EQ26796568-F96764FD-6B9E-4C70-9897-21007C16D6AAQ26825053-B1303F21-9EB6-4C3B-818D-93F812238944Q27009424-3804A1E5-846F-4EE1-8740-428CABD1866DQ27011642-4BB3473A-0B8B-49CF-AFC5-D3E46E0B94BDQ27022821-48223ED5-72D6-4C4E-B930-825B79338947Q33620520-47B107E9-EFC1-4285-A718-E35281BE5483Q33656820-E9CF7529-CE11-460D-BE8C-C8728AF71828Q33775717-DB2F512E-2979-4A0B-B48C-66DAAA59F994Q34365632-2516069F-50C1-4828-9596-AD50F7C8DF64Q34375823-1A2AFC79-11AA-4415-BFDC-20850FB85B1CQ34441134-77439FF9-E508-4F54-BFC8-08F32577C67FQ34495028-C9C06955-46C4-4F42-A6D1-5630E7497EFEQ35213324-619A87AB-A505-476A-B1CF-646EE2C6CA0DQ35553876-AF3CBB56-1EE8-4CA0-BEFC-6CCD4A29B790Q35931391-897C4438-BB12-40D4-8F7B-66F040904A9AQ36063723-413751BC-8AAC-4E25-8310-DEE494C431E6Q36298863-66D6507B-DD7B-42C8-BF3B-4E0B8225E6D2Q36849142-0894D6D0-7A87-47A9-9D7F-1E6E4F92471AQ36905832-0339F250-B4E7-4067-89CD-04FB9D39A291Q36970812-E8568724-6239-4966-9993-DB694D4FFB60Q37550399-525A81E8-89ED-4BDB-8100-AA8D1A25D781Q38176143-D0A7C492-9292-422F-A7D0-F7110CE3A74FQ38184622-39A08AEE-B45D-43F3-BFAF-FA6C66FFC342Q38195723-C1AECB62-D7EB-4F9B-83F1-61C8453D45F8Q38206682-31BA6B09-7B12-40BE-B0D6-68C0823BB8F3Q38212470-F8944341-6B9F-462F-9421-D7B065BF2ED5Q38212716-2C995549-DF68-44EA-9981-D3E34EC3AE62Q38220073-F7436E6F-18CC-44FC-9A48-C4A809F5FE38Q38259197-36DA9649-89DB-4E46-A068-EBAC98028547Q38267175-0818565B-6DE8-4A35-8DFB-A4A2A364C534Q38276818-DB80CEA1-74D6-4BBA-B11D-D56B7FE56DD6Q38282461-1DDF6B83-6972-47E3-B744-922DC0E94CA5Q38306052-FA4B6B0E-D207-407D-BAB9-738BC0B71DAAQ38312041-D22E11A0-0CD8-41A9-B0DC-D6908268D8E8Q38375252-BD64C6F8-4A81-482D-B8A9-D2C0AAE60846Q38387844-96D61A8F-C743-4E0C-9084-3349E1A25678Q38391800-B8BFE387-2320-48DC-B832-FBC25DCE574BQ38392787-318BC47F-8A70-432E-8CF0-3E3F6A0773BF
P2860
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@ast
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@en
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@nl
type
label
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@ast
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@en
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@nl
prefLabel
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@ast
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@en
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P356
P1476
Phase I study of ARN-509, a no ...... ion-resistant prostate cancer.
@en
P2093
Charles L Sawyers
Daniel C Danila
Edna Chow Maneval
Howard I Scher
Jeffrey H Hager
Josef J Fox
Martin Fleisher
Michael J Morris
Mithat Gönen
P2860
P304
P356
10.1200/JCO.2013.50.1684
P407
P577
2013-09-03T00:00:00Z